BT Investment Management Ltd Raises Position in Alexion Pharmaceuticals, Inc. (ALXN)

BT Investment Management Ltd increased its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1,911.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,636 shares of the biopharmaceutical company’s stock after purchasing an additional 22,461 shares during the period. BT Investment Management Ltd’s holdings in Alexion Pharmaceuticals were worth $2,827,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ALXN. Valeo Financial Advisors LLC acquired a new position in shares of Alexion Pharmaceuticals during the 3rd quarter worth approximately $147,000. Dupont Capital Management Corp acquired a new position in shares of Alexion Pharmaceuticals during the 3rd quarter worth approximately $156,000. Beacon Investment Advisory Services Inc. acquired a new position in shares of Alexion Pharmaceuticals during the 3rd quarter worth approximately $201,000. Invictus RG acquired a new position in shares of Alexion Pharmaceuticals during the 3rd quarter worth approximately $202,000. Finally, ETRADE Capital Management LLC acquired a new position in shares of Alexion Pharmaceuticals during the 3rd quarter worth approximately $210,000. Hedge funds and other institutional investors own 94.04% of the company’s stock.

In other news, SVP Heidi L. Wagner sold 1,774 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total transaction of $206,333.94. Following the completion of the sale, the senior vice president now directly owns 47,212 shares of the company’s stock, valued at approximately $5,491,227.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Heidi L. Wagner sold 655 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $117.26, for a total transaction of $76,805.30. Following the sale, the senior vice president now directly owns 32,635 shares of the company’s stock, valued at $3,826,780.10. The disclosure for this sale can be found here. Insiders have sold a total of 28,930 shares of company stock valued at $3,378,199 over the last three months. Corporate insiders own 4.35% of the company’s stock.

Several research analysts recently issued reports on ALXN shares. Royal Bank of Canada lifted their price objective on Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Stifel Nicolaus lowered their target price on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a research note on Tuesday, October 24th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 target price for the company in a research note on Tuesday, October 31st. Credit Suisse Group reaffirmed a “buy” rating and issued a $166.00 target price on shares of Alexion Pharmaceuticals in a research note on Tuesday, December 12th. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $169.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, December 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and twenty-one have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $153.14.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $108.60 on Friday. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $149.34. The stock has a market cap of $24,260.00, a price-to-earnings ratio of 55.13, a PEG ratio of 0.98 and a beta of 1.16. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. During the same period in the previous year, the company earned $1.26 EPS. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. sell-side analysts predict that Alexion Pharmaceuticals, Inc. will post 4.82 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “BT Investment Management Ltd Raises Position in Alexion Pharmaceuticals, Inc. (ALXN)” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://sportsperspectives.com/2018/02/10/bt-investment-management-ltd-raises-position-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply